GTx, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
50 Pages - GMD12081


Global Markets Direct’s, ‘GTx, Inc. - Product Pipeline Review - 2014’, provides an overview of the GTx, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GTx, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of GTx, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GTx, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GTx, Inc.’s pipeline products

Reasons to buy

- Evaluate GTx, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GTx, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GTx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GTx, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GTx, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GTx, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GTx, Inc. Snapshot 5
GTx, Inc. Overview 5
Key Information 5
Key Facts 5
GTx, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
GTx, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
GTx, Inc. - Pipeline Products Glance 11
GTx, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
GTx, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
GTx, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
GTx, Inc. - Drug Profiles 15
enobosarm 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
GTx-758 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Gtx-027 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Beta-LGND2 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Gtx-186 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gtx-230 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Inhibit AKR1C3 for Prostate Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Inhibit Tubulin for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GTx, Inc. - Pipeline Analysis 25
GTx, Inc. - Pipeline Products by Target 25
GTx, Inc. - Pipeline Products by Route of Administration 27
GTx, Inc. - Pipeline Products by Molecule Type 28
GTx, Inc. - Pipeline Products by Mechanism of Action 29
GTx, Inc. - Recent Pipeline Updates 31
GTx, Inc. - Dormant Projects 40
GTx, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
GTx-758 41
toremifene citrate 41
GTx, Inc. - Company Statement 42
GTx, Inc. - Locations And Subsidiaries 48
Head Office 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
GTx, Inc., Key Information 5
GTx, Inc., Key Facts 5
GTx, Inc. - Pipeline by Indication, 2014 8
GTx, Inc. - Pipeline by Stage of Development, 2014 9
GTx, Inc. - Monotherapy Products in Pipeline, 2014 10
GTx, Inc. - Phase III, 2014 11
GTx, Inc. - Phase II, 2014 12
GTx, Inc. - Phase I, 2014 13
GTx, Inc. - Preclinical, 2014 14
GTx, Inc. - Pipeline by Target, 2014 26
GTx, Inc. - Pipeline by Route of Administration, 2014 27
GTx, Inc. - Pipeline by Molecule Type, 2014 28
GTx, Inc. - Pipeline Products by Mechanism of Action, 2014 30
GTx, Inc. - Recent Pipeline Updates, 2014 31
GTx, Inc. - Dormant Developmental Projects,2014 40
GTx, Inc. - Discontinued Pipeline Products, 2014 41

List of Figures
GTx, Inc. - Pipeline by Top 10 Indication, 2014 7
GTx, Inc. - Pipeline by Stage of Development, 2014 9
GTx, Inc. - Monotherapy Products in Pipeline, 2014 10
GTx, Inc. - Pipeline by Top 10 Target, 2014 25
GTx, Inc. - Pipeline by Top 10 Route of Administration, 2014 27
GTx, Inc. - Pipeline by Top 10 Molecule Type, 2014 28
GTx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 29


Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.
+1 212 564 2838
+1 212 564 8133 fax